Chardan Capital Issues Pessimistic Forecast for Zura Bio (NASDAQ:ZURA) Stock Price

Zura Bio (NASDAQ:ZURA) had its target price dropped by analysts at Chardan Capital from $12.00 to $10.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

A number of other equities analysts also recently commented on the stock. HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a research note on Tuesday, December 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Zura Bio currently has a consensus rating of “Buy” and a consensus target price of $15.40.

Zura Bio Stock Up 10.4 %

Shares of NASDAQ ZURA opened at $1.49 on Wednesday. The company has a fifty day moving average price of $1.49 and a 200 day moving average price of $2.77. Zura Bio has a 1-year low of $1.07 and a 1-year high of $6.35.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. As a group, sell-side analysts forecast that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Institutional Trading of Zura Bio

Hedge funds and other institutional investors have recently bought and sold shares of the business. American Century Companies Inc. bought a new position in shares of Zura Bio during the fourth quarter worth approximately $27,000. Prudential Financial Inc. bought a new position in Zura Bio during the 4th quarter worth $28,000. Two Sigma Advisers LP acquired a new position in Zura Bio in the 4th quarter valued at $32,000. ProShare Advisors LLC bought a new stake in shares of Zura Bio during the 4th quarter valued at $35,000. Finally, XTX Topco Ltd bought a new stake in shares of Zura Bio during the 4th quarter valued at $44,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.